[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362995-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362995-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","otud4-inhibits-prostate-cancer-by-deubiquitinating-myh9","OTUD4 Inhibits Prostate Cancer by Deubiquitinating MYH9","","Objective: Prostate cancer ranks as the second most common fatal cancer in men, and new biological therapeutic targets are needed to improve patient prognosis. OTUD4, an ovarian tumor family deubiquitinase, has unclear relevance to prostate cancer. Methods: The study used cell culture and multiple functional assays alongside molecular analyses, in vivo xenograft models, and histology. Results: OTUD4 is reduced in prostate cancer and associates with poor prognosis; mechanistically, it deubiquitinates MYH9 and blocks MYH9 degradation. Conclusion: OTUD4 acts as a tumor suppressor by preserving MYH9-mediated inhibition of prostate cancer growth.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/otud4-inhibits-prostate-cancer-by-deubiquitinating-myh9/362995/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/otud4-inhibits-prostate-cancer-by-deubiquitinating-myh9/362995.png","ImageObject",300,407,{"name":42,"@type":43},"นรินทร์","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this study on prostate cancer?","Question",{"text":63,"@type":64},"To explore potential therapeutic targets and diagnostic markers for prostate cancer and investigate how OTUD4 functions in this disease.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How are OTUD4 and patient outcomes related?",{"text":68,"@type":64},"OTUD4 expression is reduced in prostate cancer and negatively correlated with poor prognosis in both in vivo and in vitro experiments.",{"name":70,"@type":61,"acceptedAnswer":71},"What mechanism does the study propose for OTUD4’s tumor-suppressing effect?",{"text":72,"@type":64},"OTUD4 directly inhibits degradation of MYH9 by deubiquitinating MYH9, enabling MYH9-mediated suppression of prostate cancer growth.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362995,1791037663,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":117,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":103,"preview_page_count":33,"preview_urls":144},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Tech Science Press  \n| Doi:10.32604/or.2025.073455\u003Cbr>ARTICLE | \u003Cbr>|\n| --- | --- |\n| OTUD4 Inhibits Prostate Cancer by Deubiquitinating MYH9\u003Cbr>Zheng Qin1,2,\\#, Yueyao Zhang3,\\#, Dongze Liu4,\\#, Xiaokang Zheng5, Kaibin Wang1,2, Xiao Zhu1,2, Yuanhao Zhang1,2, Kexin Xu1,2, Changying Li1,2, Lijuan Kang1,2, Lili Wang1,2 and Haitao Wang1,2, *\u003Cbr>1 Tianjin Key Laboratory of Precision Medicine for Sex Hormones and Diseases, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China\u003Cbr>2 Department of Oncology, The Second Hospital of Tianjin Medical University, Tianjin, 300211, China 3 Department of Cell Biology, Peking University Cancer Hospital & Institute, Beijing, 100142, China 4 Department of Urology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, 150001, China 5 Department of Urology, The Henan Provincial People’s Hospital, Zhengzhou, 462000, China\u003Cbr>*[Corresponding Author: Haitao Wang. Email: wanght@tmu.edu.cn](Corresponding Author: Haitao Wang. Email: wanght@tmu.edu.cn)\u003Cbr>\\# These authors contributed equally to this work\u003Cbr>Received: 18 September 2025; Accepted: 23 December 2025; Published: 23 March 2026\u003Cbr>ABSTRACT: Objective: Prostate cancer is the second most common fatal cancer in men. Identifying new biological therapeutic targets is crucial to effectively improve the prognosis of prostate cancer patients. Ovarian tumor family deubiquitinase 4 (OTUD4) is a member of the ovarian tumor-associated protease domain (OTUDs) family. Although previous studies have shown that the expression and function of OTUD4 vary across different tumors, its role in prostate cancer remains unknown. The aim of this study is to explore new therapeutic targets and diagnostic markers for prostate cancer and investigate their mechanisms of action. Methods: Cell culture, Cell Counting Kit-8 (CCK-8) assay, colony formation assay, Transwell assay, 5-Ethynyl-2′ -deoxyuridine (EdU) assay, immunofluorescence, Western blot, Quantitative real-time PCR (qRT-PCR), protein mass spectrometry, nude mouse xenograft models, immunohistochemistry (IHC), and hematoxylin and eosin (H&E) staining were utilized. Results: We found that OTUD4 expression was reduced in prostate cancer and negatively correlated with poor prognosis in both in vivo and in vitro experiments. Subsequent mechanistic studies revealed that OTUD4 directly inhibits the degradation of myosin-9 (MYH9) protein via deubiquitination. Although MYH9 has been previously reported to act as a tumor suppressor in prostate cancer, no experimental evidence had demonstrated that MYH9 inhibits prostate cancer growth. Our results indicate that MYH9 overexpression effectively suppresses prostate cancer through interactions with cell adhesion molecules. Conclusion: Collectively, these results suggest that OTUD4 functions as a tumor suppressor in prostate cancer. Specifically, OTUD4 inhibits MYH9 degradation via deubiquitination, thereby enabling MYH9-mediated suppression of prostate cancer.\u003Cbr>KEYWORDS: Prostate cancer; ovarian tumor family deubiquitinase 4 (OTUD4); therapeutic target; myosin-9 (MYH9); ubiquitin (UB) |  |\n\n1 Introduction  \nProstate cancer has become the second cancer leading cause of cancer death and places a heavy burden on global healthcare [1] . According to cancer statistics for 2023, the incidence of prostate cancer is rising by approximately 3% annually, equivalent to about 99,000 new cases per year [2] . Importantly, the growth of prostate cancer depends on androgens in the male body; therefore, androgen deprivation therapy (ADT) remains the cornerstone of early prostate cancer treatment. ADT can inhibit prostate cancer growth and  \nCopyright © 2026 The Authors. Published by Tech Science Press.  \nThis work is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.  \ndelay clinical tumor progression [3]. However, after","cbCaidXAJyIikQJ0","https://ap.wps.com/l/cbCaidXAJyIikQJ0","pdf",43902563,"English","# Abstract\n# 1 Introduction\n## Background and clinical context\n## Androgen deprivation therapy and resistance\n## Protein degradation systems and ubiquitin-proteasome pathway","[{\"question\":\"What is the main purpose of this study on prostate cancer?\",\"answer\":\"To explore potential therapeutic targets and diagnostic markers for prostate cancer and investigate how OTUD4 functions in this disease.\"},{\"question\":\"How are OTUD4 and patient outcomes related?\",\"answer\":\"OTUD4 expression is reduced in prostate cancer and negatively correlated with poor prognosis in both in vivo and in vitro experiments.\"},{\"question\":\"What mechanism does the study propose for OTUD4’s tumor-suppressing effect?\",\"answer\":\"OTUD4 directly inhibits degradation of MYH9 by deubiquitinating MYH9, enabling MYH9-mediated suppression of prostate cancer growth.\"}]","OTUD4 Inhibits Prostate Cancer by Deubiquitinating MYH9 | PDF",1790149607,[145,149,153,157],{"page_no":22,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/38def57acb19d31d074ad8999e0ef9e6.webp",983,1271,{"page_no":26,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6408754eca9bdeddaecf54fa950f6f9c.webp",982,1270,{"page_no":30,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9028756297b06d5dbedf11d14e6bcb8.webp",981,1269,{"page_no":33,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f9962c01ed41990d7d8d03447a3148d.webp",980,1267]